Metropolis Healthcare Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Metropolis Healthcare presented its business strategy, growth engines, and margin ambitions at an Investor and Analyst Meet, reporting FY26 revenue of Rs 1,646 crore and a three-year revenue CAGR of 17.6%. Management described plans to expand specialty testing, genomics, TruHealth bundles, and a new radiology mini-hub format, while maintaining a medium-term revenue growth guidance of 14%-15% delivered at 17% in the most recent quarter. Management also discussed margin improvement plans, targeting EBITDA margin expansion from 24.4% toward 27%-28% through mix improvement, productivity, and network utilization.
Metropolis Healthcare reported Q4 FY26 group revenue of Rs 425 crore, up 23% year-on-year, with an EBITDA margin of 25.4%, while full year FY26 revenue reached Rs 1,646 crore, up 23.6%. Organic revenue growth for the year was 13.7%, ahead of the company's stated 12-13% guidance, with organic EBITDA margin expanding to 25.9%. Management also discussed the integration of Core Diagnostics, which reached a high-single-digit EBITDA margin in Q4, and outlined plans for network expansion including mini hubs and additional collection centers over the next three years.